State ex rel. Owens v. Indus. Comm. , 2018 Ohio 1160 ( 2018 )


Menu:
  • [Cite as State ex rel. Owens v. Indus. Comm., 2018-Ohio-1160.]
    IN THE COURT OF APPEALS OF OHIO
    TENTH APPELLATE DISTRICT
    State ex rel. John R. Owens,                           :
    Relator,                               :
    v.                                                     :             No. 17AP-97
    Industrial Commission of Ohio et al.,                  :          (REGULAR CALENDAR)
    Respondents.                           :
    D E C I S I O N
    Rendered on March 29, 2018
    On brief: Law Offices of Kurt M. Young, LLC, Kurt M.
    Young, and Emil G. Gravelle, III, for relator.
    On brief: Michael DeWine, Attorney General, and John
    Smart, for respondent Industrial Commission of Ohio.
    IN MANDAMUS
    ON OBJECTIONS TO THE MAGISTRATE'S DECISION
    KLATT, J.
    {¶ 1} Relator, John R. Owens, commenced this original action in mandamus
    seeking an order compelling respondent, Industrial Commission of Ohio ("commission"),
    to vacate its order denying him reimbursement for a prescription medication ("Voltaren
    gel") and to enter a new order that requires the commission to reimburse him for that
    medication.
    {¶ 2} Pursuant to Civ.R. 53 and Loc.R. 13(M) of the Tenth District Court of Appeals,
    we referred this matter to a magistrate who issued a decision, including findings of fact and
    conclusions of law, which is appended hereto. The magistrate found that the commission
    did not violate relator's due process rights during a drug utilization review of relator's
    No. 17AP-97                                                                                  2
    medications. The magistrate further found that Dr. Bridger's report constituted some
    evidence supporting the commission's decision to deny reimbursement for the Voltaren gel.
    Therefore, the magistrate has recommended that we deny relator's request for a writ of
    mandamus.
    {¶ 3} Relator has filed objections to the magistrate's decision. In his first objection,
    relator contends that his due process rights were violated because a nurse working for the
    employer's managed care organization ("MCO") initiated the review of relator's
    medications. We disagree.
    {¶ 4} Because relator was provided with reasonable notice and a reasonable
    opportunity to be heard, we agree with the magistrate that the commission did not violate
    relator's due process rights. State ex rel. Charles Steinbrunner v. Indus. Comm., 10th Dist.
    No. 05AP-626, 2006-Ohio-3444, ¶ 16, quoting State ex rel. Finley v. Dusty Drilling, Co.,
    Inc., 
    2 Ohio App. 3d 323
    , 324-25 (10th Dist.1981) (" '[p]rocedural due process includes the
    right to a reasonable notice of hearing as well as a reasonable opportunity to be heard' ").
    Following the MCO's nonbinding decision, relator received two administrative hearings on
    the drug reimbursement issue. The fact that the employer's MCO initiated the drug
    utilization review, rather than the bureau or the commission, does not impact the due
    process analysis. Relator had notice and participated in multiple levels of administrative
    review. Therefore, we overrule relator's first objection.
    {¶ 5} In his second objection, relator contends that Dr. Bridger's report is not some
    evidence on which the commission could rely because it allegedly reflects an "uncertain
    opinion." Again, we disagree.
    {¶ 6} Contrary to relator's assertion, we fail to discern uncertainty in Dr. Bridger's
    report. Despite Dr. Bridger's use of the word "appears," we agree with the magistrate that
    Dr. Bridger's report clearly indicates he believed prescribing Voltaren gel was unnecessary
    given the Celebrex prescription. Because Dr. Bridger's report is some evidence on which
    the commission could rely, the commission did not abuse its discretion in denying relator's
    request for reimbursement for the Voltaren gel. Therefore, we overrule relator's second
    objection.
    {¶ 7} Following an independent review of this matter, we find that the magistrate
    has properly determined the facts and applied the appropriate law. Therefore, we adopt
    No. 17AP-97                                                                             3
    the magistrate's decision as our own, including the findings of fact and conclusions law
    contained therein. In accordance with the magistrate's decision, we deny relator's request
    for a writ of mandamus.
    Writ of mandamus denied.
    TYACK and SADLER, JJ., concur.
    No. 17AP-97                                                                            4
    APPENDIX
    IN THE COURT OF APPEALS OF OHIO
    TENTH APPELLATE DISTRICT
    The State ex rel. John R. Owens,             :
    Relator,                       :
    v.                                           :                   No. 17AP-97
    Industrial Commission of Ohio, et al.,      :              (REGULAR CALENDAR)
    Respondents.                   :
    MAGISTRATE'S DECISION
    Rendered on September 26, 2017
    Law Offices of Kurt M. Young, LLC, Kurt M. Young, and Emil
    G. Gravelle, III, for relator.
    Michael DeWine, Attorney General, and John Smart, for
    respondent Industrial Commission of Ohio.
    IN MANDAMUS
    {¶ 8} Relator, John R. Owens, has filed this original action requesting this court
    issue a writ of mandamus ordering respondent Industrial Commission of Ohio
    ("commission") to vacate its order which denied him reimbursement for a prescription
    medication, and ordering the commission to reimburse him for that medication.
    Findings of Fact:
    {¶ 9} 1. Relator sustained a work-related injury on July 9, 2014 and his workers'
    compensation claim has been allowed for: "left shoulder region contusion; subscapularis
    tendon tear partial left."
    No. 17AP-97                                                                               5
    {¶ 10} 2. In June 2015, relator began treating with Nathan Hill, M.D., a pain
    specialist.
    {¶ 11} 3. Although physical therapy provided some relief, relator continued to
    have muscle pain around his left shoulder. As a result, Dr. Hill prescribed Voltaren topical
    gel, a non-steroidal anti-inflammatory drug ("NSAID").
    {¶ 12} 4. Because relator's pain was not subsiding, Dr. Hill submitted a C-9 for
    shoulder injections and a 30-day trial of a tens unit. Dr. Hill also prescribed relator
    Celebrex, 200 milligrams, and Ultram, 50 milligrams, and continued him using the
    Voltaren gel. Celebrex is also a NSAID.
    {¶ 13} 5. 1-888-Ohio Comp, the employer's managed care organization ("MCO"),
    denied the request for additional occupational therapy, a tens unit, cortisone injections,
    and a subsequent MRI of relator's shoulder. The MCO provided the following rationale:
    Based on your request for services, review of medical records
    and consideration of nationally accepted guidelines, it is the
    opinion of this MCO that the requested services do not appear
    to be medically indicated or appropriate. Injured worker has
    been previously approved for conservative treatment of
    physical therapy 16 visits total. The physical therapy notes
    dated 10/7/2014 state the injured worker reports pain most of
    the time is 1/10 on scale and shows compliance with home
    exercise program and good understanding of exercise
    program, he will continue to strengthen at home. Injured
    worker has had a lapse of treatment of over 10 months. This
    would suggest that injury has been resolved. Fails Miller
    criteria #2 and #3.
    ***
    Based on your request for services, review of medical records
    and consideration of nationally accepted guidelines, it is the
    opinion of this MCO that the requested services do not appear
    to be medically indicated or appropriate. Injured worker has
    been authorized for 2 previous left shoulder MRI's. Injured
    worker was last seen for shoulder on 11/4/2014 prior to recent
    notes from Dr. Hill dated 7/3/2015. Injured worker has had a
    lapse of treatment of over 10 months. This would suggest that
    injury has been resolved. Fails Miller criteria #2 and #3.
    No. 17AP-97                                                                             6
    {¶ 14} 6. Relator challenged the denial of services and the matter was heard before
    a district hearing officer ("DHO") on November 12, 2015. The DHO granted relator's
    request for two shoulder injections, denied the requested occupational therapy evaluation
    and treatment, and the requested tens unit trial. At the hearing, counsel dismissed the
    requested right shoulder MRI.
    {¶ 15} 7. Relator appealed and the matter was heard before a staff hearing officer
    ("SHO") on January 6, 2016. The SHO modified the prior DHO order and authorized the
    requested two left shoulder injections as well as the occupational therapy evaluation and
    treatment. The SHO did deny the 30-day trial of the tens unit.
    {¶ 16} 8. On April 6, 2016, "Jill P. RN," who works for the MCO, requested a
    Medco-34 to review the reasonableness, necessity, and appropriateness of the
    prescription medications relator was using. The MCO notified relator, through counsel,
    of the drug utilization review.
    {¶ 17} 9. Matthew A. Bridger, M.D., reviewed relator's relevant medical records
    and performed a drug utilization review. In his April 30, 2016 report, Dr. Bridger
    identified the allowed conditions in relator's claim as follows:
    The allowed condition for the use of the medications is
    S46912A - "strain Of Unspecified Muscle, Fascia And Tendon
    At Shoulder And Upper Arm Level, Left Arm, Initial
    Encounter." This diagnosis is also used for additional
    allowance approval for partial subscapularis tear, left
    shoulder. The diagnosis was confirmed on an 08/2014 MRI.
    {¶ 18} Thereafter, Dr. Bridger stated:
    The treatment has not involved injections or surgery, but
    treated conservatively with PT and medications. The other
    diagnoses are soft tissue injury and have resolved MONTHS
    ago. The [Injured Worker] has been released to full duty for
    months. There appears to be redundancy of NSAIA use with
    celebrex and voltaren (topical). Recent note from Dr. Hill has
    refills for celebrex. The cost of the medications is not included
    in the pharmacy materials, but is assumed to be within the
    standard of care for the indicated medications. It is with a
    reasonable degree of medical certainty that this physician (13
    years of occupational medicine experience) opines:
    No. 17AP-97                                                                             7
    (1) The medical reviewed SUPPORTS adequate prescribing
    physician information to medically justify the use of Celebrex
    and ultram being utilized by the injured worker as medically
    necessary, appropriate and reasonably related to treatment of
    symptoms associated with the allowed condition for this
    claim. The medical reviewed DOES NOT SUPPORT adequate
    prescribing physician information to medically justify the use
    of voltaren being utilized by the injured worker as medically
    necessary, appropriate nor reasonably related to treatment of
    symptoms associated with the allowed condition for this
    claim.
    (2) The medical reviewed SUPPORTS the specific drug dosing
    and duration for celebrex and ultram to be reasonably related,
    medically reasonable and appropriate for the allowed
    condition(s) for this claim. The medical reviewed DOES NOT
    SUPPORT the specific drug dosing and duration for voltaren
    to be reasonably related, medically reasonable and
    appropriate for the allowed condition for this claim.
    (3) There are NO potentially harmful effects for the use and
    compliance monitoring by a pain specialist for the
    continuance of the listed medications. There is NO
    documentation to support redundant use of NSAIA. The
    combination of currently prescribed indicated drugs is in
    compliance with best practices for the allowed condition in
    this claim.
    (Emphasis sic.)
    {¶ 19} 10. In an order mailed May 5, 2016, the Ohio Bureau of Workers'
    Compensation ("BWC") denied reimbursement for the Voltaren gel based on the
    physician review of Dr. Bridger.
    {¶ 20} 11. Relator appealed and the matter was heard before a DHO on June 15,
    2016. The DHO affirmed the order of the administrator and denied reimbursement for
    the use of Voltaren gel based on the report of Dr. Bridger. Thereafter, the DHO addressed
    relator's argument that Dr. Bridger's report and the Medco-34 request for drug utilization
    review should be dismissed because it was not signed by the MCO's medical director. The
    DHO rejected that argument, stating:
    Preliminarily, the District Hearing Officer notes the Injured
    Worker's argument that Dr. Bridger's report and the MEDCO-
    No. 17AP-97                                                                               8
    34 Managed Care Organization (MCO) Request for Drug
    Utilization Review (DUR) should be dismissed, as the
    MEDCO-34 form was not signed by the MCO medical
    director. The Injured Worker's representative based this
    argument on Chapter 7 of a Bureau of Workers' Compensation
    publication which was not cited by name. Additionally, the
    Injured Worker did not provide the Hearing Officer with a
    copy of such authority. As this issue was reviewed by Dr.
    Bridger, and as he duly signed his 04/30/2016 report, the
    District Hearing Officer rejects the Injured Worker's
    argument to dismiss the MEDCO-34 at issue.
    {¶ 21} 12. Relator appealed and the matter was heard before an SHO on August 5,
    2016. The SHO affirmed the prior DHO order and denied reimbursement for relator's
    Voltaren gel based on the report of Dr. Bridger. The SHO also rejected relator's argument
    concerning the validity of the review, stating:
    The Staff Hearing Officer rejects the argument of the Injured
    Worker's representative that Dr. Bridger's report is not some
    evidence on which to rely as the Injured Worker's
    representative indicates that the guidelines for obtaining a
    drug utilization review were not followed in this claim. The
    Staff Hearing Officer finds no mandatory requirement that
    the request for a drug utilization review must be signed by a
    managed care organization physician or medical director. The
    request was made by Jill P., R.N. This R.N. completed claims
    notes which are contained in the claim file dated 04/06/2016
    wherein R.N. "Jill" explains the need for the drug review
    request. The request was forwarded to Dr. Bridger to do the
    drug utilization review. Dr. Bridger signed his report which
    contains his medical opinion and Dr. Bridger is a duly licensed
    medical doctor. As such, his review is found to be some
    evidence on which the Industrial Commission can rely.
    {¶ 22} 13. Relator's appeal was refused by order of the commission mailed
    August 31, 2016.
    {¶ 23} 14. Thereafter, relator filed this instant mandamus action in this court.
    Conclusions of Law:
    {¶ 24} For the reasons that follow, it is this magistrate's decision that this court
    should deny relator's request for a writ of mandamus.
    No. 17AP-97                                                                                 9
    {¶ 25} The Supreme Court of Ohio has set forth three requirements which must be
    met in establishing a right to a writ of mandamus: (1) that relator has a clear legal right to
    the relief prayed for; (2) that respondent is under a clear legal duty to perform the act
    requested; and (3) that relator has no plain and adequate remedy in the ordinary course
    of the law. State ex rel. Berger v. McMonagle, 
    6 Ohio St. 3d 28
    (1983).
    {¶ 26} In order for this court to issue a writ of mandamus as a remedy from a
    determination of the commission, relator must show a clear legal right to the relief sought
    and that the commission has a clear legal duty to provide such relief. State ex rel. Pressley
    v. Indus. Comm., 
    11 Ohio St. 2d 141
    (1967). A clear legal right to a writ of mandamus exists
    where the relator shows that the commission abused its discretion by entering an order
    which is not supported by any evidence in the record. State ex rel. Elliott v. Indus. Comm.,
    
    26 Ohio St. 3d 76
    (1986). On the other hand, where the record contains some evidence to
    support the commission's findings, there has been no abuse of discretion and mandamus
    is not appropriate. State ex rel. Lewis v. Diamond Foundry Co., 
    29 Ohio St. 3d 56
    (1987).
    Furthermore, questions of credibility and the weight to be given evidence are clearly
    within the discretion of the commission as fact finder. State ex rel. Teece v. Indus.
    Comm., 
    68 Ohio St. 2d 165
    (1981).
    {¶ 27} Relator makes the following two arguments: (1) he was denied due process
    of law when the commission processed the Medco-34 drug utilization review ("DUR")
    request when it was not submitted pursuant to the guidelines of the Ohio Administrative
    Code; and (2) the commission abused its discretion when it decided not to reimburse
    relator for the Voltaren gel.
    {¶ 28} Relator is correct to assert that due process rights are implicated in
    administrative proceedings such as those before the commission. As this court explained
    in State ex rel. Steinbrunner v. Indus. Comm., 10th Dist. No. 05AP-626, 2006-Ohio-
    3444:
    As applied to proceedings before the commission,
    "[p]rocedural due process includes the right to a reasonable
    notice of hearing as well as a reasonable opportunity to be
    heard." 
    Id. at 324-325.
    "Furthermore, the right to a
    reasonable opportunity to be heard includes reasonable notice
    of the time, date, location and subject matter of the hearing."
    State ex rel. LTV Steel Co. v. Indus. Comm. (1995), 102 Ohio
    No. 17AP-97                                                                              10
    App.3d 100, 103-104, 
    656 N.E.2d 1016
    . Without reasonable
    notice of the hearing's subject matter, a party's right to appear
    and present well-supported and developed arguments
    endorsing his position is compromised.
    
    Id. at ¶
    16.
    {¶ 29} In support of his argument that the drug utilization review was not properly
    before the commission, relator cites R.C. 4121.32(C)(2), which provides:
    (C) The bureau and commission jointly shall develop, adopt,
    and use a policy manual setting forth the guidelines and bases
    for decision-making for any decision which is the
    responsibility of the bureau, district hearing officers, staff
    hearing officers, or the commission. Guidelines shall be set
    forth in the policy manual by the bureau and commission to
    the extent of their respective jurisdictions for deciding at least
    the following specific matters:
    ***
    (2) Relationship of drugs to injury.
    Relator also cites Ohio Adm.Code 4123-6-21(P), which provides:
    The bureau may contract with a pharmacy benefit manager to
    perform drug utilization review and on-line bill processing,
    maintain a pharmacy provider network and prior
    authorization program for medications, and provide
    management reports. The bureau or its vendor may also
    contract rebate agreements with drug manufacturers. The
    bureau may utilize other services or established procedures of
    the pharmacy benefits manager which may enable the bureau
    to control costs and utilization and detect fraud.
    {¶ 30} Relator argues that his due process rights were violated when a nurse
    working for the employer's MCO initiated the review of the medications which relator was
    taking. Contrary to relator's assertions, neither the BWC nor the commission initiated
    the review of his medications and, as such, the statute and code provisions on which he
    relies do not apply here. To the extent that there is any due process argument to be made,
    the magistrate specifically notes that relator received two hearings on the matter. Clearly,
    relator was provided with notice and an opportunity to be heard and, as such, there was
    no due process violation.
    No. 17AP-97                                                                             11
    {¶ 31} Relator's second argument is that the commission abused its discretion
    when it denied reimbursement for the Voltaren gel. Here, the commission relied on the
    review of Dr. Bridger who specifically opined that there appeared to be redundancy
    through the use of Celebrex and Voltaren gel, both NSAIDS, and that the medical evidence
    review did not support the justification of using the Voltaren gel in addition to the
    Celebrex. The magistrate finds that the report of Dr. Bridger does constitute some
    evidence on which the commission could rely and, as such, relator has not demonstrated
    that the commission abused its discretion.
    {¶ 32} Based on the foregoing, it is this magistrate's decision that relator has not
    demonstrated that the commission abused its discretion when it denied reimbursement
    for Voltaren gel and this court should deny his request for a writ of mandamus.
    /S/ MAGISTRATE
    STEPHANIE BISCA
    NOTICE TO THE PARTIES
    Civ.R. 53(D)(3)(a)(iii) provides that a party shall not assign as
    error on appeal the court's adoption of any factual finding or
    legal conclusion, whether or not specifically designated as a
    finding of fact or conclusion of law under Civ.R. 53(D)(3)(a)(ii),
    unless the party timely and specifically objects to that factual
    finding or legal conclusion as required by Civ.R. 53(D)(3)(b).
    

Document Info

Docket Number: 17AP-97

Citation Numbers: 2018 Ohio 1160

Judges: Klatt

Filed Date: 3/29/2018

Precedential Status: Precedential

Modified Date: 3/29/2018